Replies to post #93537 on Biotech Values

[DewDiligence]

Consummation of the Eloxatin settlement was almost certainly held up until the healthcare law was passed—without the threatened provision on Pay for Delay.

I like this quote from today’s WSJ:

http://online.wsj.com/article/SB10001424052702304355804575157140782182392.html

“It looks like another pay-for-delay deal, but it's not clear who is paying what,” said Fiske analyst Peter Cartwright, referring to the lack of details on the agreement.

p.s. HSP joined the settlement on the same terms as TEVA and NVS.

[DewDiligence]

SNY settles with additional Eloxatin challengers:

http://www.reuters.com/article/idCNLDE63505020100406

I think the settlement now includes every company that challenged the patent.